Irampanel (INN, code name BIIR-561) is a drug which acts as a dual noncompetitive antagonist of the AMPA receptor and neuronal voltage-gated sodium channel blocker.[1][2] It was under development by Boehringer Ingelheim for the treatment of acute stroke/cerebral ischemia but never completed clinical trials for this indication.[3][4] Irampanel was also trialed, originally, for the treatment of epilepsy and pain, but these indications, too, were abandoned,[1] and the drug was ultimately never marketed.

References

  1. ^ a b Feigin V (June 2002). "Irampanel Boehringer Ingelheim". Current Opinion in Investigational Drugs. 3 (6): 908–910. PMID 12137411.
  2. ^ Wang KK, Larner SF, Robinson G, Hayes RL (December 2006). "Neuroprotection targets after traumatic brain injury". Current Opinion in Neurology. 19 (6): 514–519. doi:10.1097/WCO.0b013e3280102b10. PMID 17102687. S2CID 28119069.
  3. ^ Sharma SS, Kaundal RK (1 January 2007). "Targeting Molecular Pathways in Stroke". In Ray A, Gulati K (eds.). Current Trends in Pharmacology. I. K. International Pvt Ltd. pp. 321–. ISBN 978-81-88237-77-7.
  4. ^ Weiser T (April 2005). "AMPA receptor antagonists for the treatment of stroke". Current Drug Targets. CNS and Neurological Disorders. 4 (2): 153–159. doi:10.2174/1568007053544129. PMID 15857300.
Allikas: https://en.wikipedia.org/wiki/Irampanel
No tags for this post.